

Univ. Prof. Dr. med. Jochen Seufert, FRCPE

General information

Univ. Prof. Dr. med. Jochen Seufert, FRCPE, male
Date of Birth: 20-Aug-1964

Full Professor of Medicine (W3),
Head
Division of Endocrinology and Diabetology
Department of Medicine II
Medical Center – University of Freiburg,
Faculty of Medicine, University of Freiburg,
Hugstetter Straße 55, 79106 Freiburg, Germany
Phone: +49-761-270-34200
Fax: +49-761-270-34130
Email: jochen.seufert@uniklinik-freiburg.de

University training and degree:

INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
University of Würzburg, Medical School, Germany	License in Medicine, Approbation	1990	Medicine
University of Würzburg, Medical School	Doctorate, M.D.	1991	Internal Medicine
Department of Internal Medicine, Endocrinology and Metabolism, University Hospital of Würzburg, Germany	Doctorate, Ph.D.	2001	Molecular Medicine

Advanced academic qualifications

INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
German Medical Board	Board Certification	2000	Internal Medicine
German Diabetes Association (DDG)	Certificate	2000	Diabetologist, DDG
German Medical Board	Board Certification	2003	Endocrinology and Diabetology
German Medical Board	Board Certification	2006	Diabetology
Royal College of Physicians of Edinburgh (FRCPE), UK	Fellow	2011	Medicine

Postgraduate professional career

Position	Institution / organisation / City, Country	Year (from - to)
Full Professor of Internal Medicine (W3), Endocrinology and Diabetology, Division Head	Division of Endocrinology and Diabetology, Department of Medicine II, Medical Centre, Medical Faculty, University of Freiburg	2006 - date
Associate Professor of Medicine	Division of Metabolism, Endocrinology and Molecular Medicine including Endocrine-Laboratory, University of Würzburg, Medical School, Germany	2001
Instructor in Medicine	Division of Metabolism, Endocrinology and Molecular Medicine , University of Würzburg Medical School, Germany	1998 – 2001
Instructor in Medicine and Endocrinology	Harvard Medical School, Boston, Massachusetts, USA	1998
Research Fellow in Molecular Endocrinology, Laboratory of Molecular Endocrinology with joint appointment in Department of Medicine	Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA	1995 - 1998
Instructor in Medicine	Department of Internal Medicine, University of Würzburg, Germany	1995
Clinical Fellow	Department of Internal Medicine, Endocrine and Gastrointestinal Unit, University of Würzburg, Germany	1992 – 1995
Chief Resident	Department of Internal Medicine, University of Würzburg, Germany	1992
Research Fellow, Clinical Research Group “Cell Differentiation and Local Regulatory Systems”	Department of Endocrinology, Metabolism and Molecular Internal Medicine, University of Würzburg, Germany	1991 – 1995
Resident in Internal Medicine	Department of Internal Medicine, Endocrine and Gastrointestinal Unit, University of Würzburg, Germany	1990 - 1992
Intern in Medicine	Department of Internal Medicine, University of Würzburg, Germany	1989 - 1990

Awards and positions in scientific associations and boards

- 1995 Career Development Award from German Research Council (Deutsche Forschungsgemeinschaft, DFG)
- 1997 Research Award from German Research Council (Deutsche Forschungsgemeinschaft, DFG)
- 1997 Travel Grant Award from Endocrine Society (Annual Meeting, Minneapolis, USA)
- 1997 Travel Grant Award from International Diabetes Federation (Meeting in Helsinki, Finland)
- 1998 Schoeller-Junkmann Scientific Award for young investigators from German Endocrine Society
- 1999 Theodor-Frerichs-Award (highest award from German Association for Internal Medicine)
- 2000 Travel Grant Award from Endocrine Society (Annual Meeting, Toronto, Canada)
- 2001 "Merck Senior Fellows Award" of the Endocrine Society, USA, in conjunction with the 83rd Scientific Meeting of the Endocrine Society (ENDO 2001), Denver, Colorado, USA.
- 2003 Young Investigator Award, German Association for Internal Medicine (109th Annual Meeting, Wiesbaden, Germany)
- 2004 Ernst-Friedrich-Pfeiffer-Award, Highest award in the field of type 1 diabetes mellitus of the German Diabetes Association (38th Annual Meeting and Scientific Sessions, Hannover, Germany)
- 2011 Honorary Fellow of the Royal College of Physicians of Edinburgh
- 2014 Member of the Presidential Committee of the German Diabetes Association (until 2019)
- 2019 Member of the Presidential Committee of the German Endocrine Society (ongoing)
- 2016 Member of the Scientific Committee for the German Diabetes Surveillance of the Robert-Koch-Institute (RKI), and the German Ministry of Health (ongoing)
- 2014 Editorial Board of "Diabetes und Stoffwechsel" (ongoing)
- 2016 Editorial Board of "Der Diabetologe" (ongoing)

Publications (Selected, 1-10)

Web of Science (18-Apr-2021): h-Index 35, 353 Publications, 4685 Citations

1. Pfohl, M., Jornayvaz, F.R., Fritsche, A., Pscherer, S., Anderten, H., Pegelow, K., and Seufert, J. 2020. Effectiveness and safety of insulin glargine 300 U/mL in insulin-naive patients with type 2 diabetes after failure of oral therapy in a real-world setting. *Diabetes Obes Metab* 22:759-766.
2. Mann, J.F.E., Hansen, T., Idorn, T., Leiter, L.A., Marso, S.P., Rossing, P., Seufert, J., Tadayon, S., and Vilsboll, T. 2020. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. *Lancet Diabetes Endocrinol* 8:880-893.
3. Seufert, J., Fritsche, A., Pscherer, S., Anderten, H., Borck, A., Pegelow, K., Bramlage, P., and Pfohl, M. 2019. Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs. *Diabetes Obes Metab* 21:439-443.
4. Pfohl, M., Pscherer, S., Fritsche, A., Anderten, H., Borck, A., Pegelow, K., Bramlage, P., and Seufert, J. 2019. Predictors of treatment response in type-2 diabetes patients initiating basal-supported oral therapy with insulin glargine 100 U/mL: A sub-analysis of the Titration and Optimisation (TOP) registry. *Diabetes Obes Metab* 21:2169-2173.
5. Kalscheuer, H., Seufert, J., Lanzinger, S., Rosenbauer, J., Karges, W., Bergis, D., Mader, J.K., Zimny, S., Schmid, S.M., Hummel, M., et al. 2019. Event Rates and Risk Factors for the Development of Diabetic Ketoacidosis in Adult Patients With Type 1 Diabetes: Analysis From the DPV Registry Based on 46,966 Patients. *Diabetes Care* 42:e34-e36.
6. Fonseca, V.A., Capehorn, M.S., Garg, S.K., Jodar Gimeno, E., Hansen, O.H., Holst, A.G., Nayak, G., and Seufert, J. 2019. Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide. *J Clin Endocrinol Metab*.

7. Jabbour, S., Seufert, J., Scheen, A., Bailey, C.J., Karup, C., and Langkilde, A.M. 2018. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. *Diabetes Obes Metab* 20:620-628.
8. Perakakis, N., Triantafyllou, G.A., Fernandez-Real, J.M., Huh, J.Y., Park, K.H., Seufert, J., and Mantzoros, C.S. 2017. Physiology and role of irisin in glucose homeostasis. *Nat Rev Endocrinol* 13:324-337.
9. Seufert, J., Bailey, T., Barkholt Christensen, S., and Nauck, M.A. 2016. Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta-analysis of seven phase III trials. *Diabetes Obes Metab* 18:721-724.
10. Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jodar, E., Leiter, L.A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M.L., et al. 2016. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med* 375:1834-1844.